✦ LIBER ✦

Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia

✍ Scribed by Vicent Guillem; Paula Amat; Francisco Cervantes; Alberto Alvarez-Larrán; Jose Cervera; Margherita Maffioli; Beatriz Bellosillo; María Collado; Isabel Marugán; Francisco Martínez-Ruiz; Juan-Carlos Hernández-Boluda

Book ID: 113773478
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 337 KB
Volume: 36
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2011.06.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

XPC genetic polymorphisms correlate with

XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia

✍ Vicent M. Guillem; Francisco Cervantes; Jesús Martínez; Alberto Alvarez-Larrán; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

PCN92 Cost-Effectiveness of Nilotinib Ve

PCN92 Cost-Effectiveness of Nilotinib Versus Imatinib as First-Line Treatment for Newly Diagnosed Patients With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Russian Federation

✍ R. Yagudina; A. Kulikov; I. Komarov 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views

Significance of suboptimal response to i

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 2 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during

A report of early cytogenetic response t

A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript

✍ Xiaoqing Li; Jing Yang; Xiangjun Chen; Jun Liu; Hongrui Li; Jine Zheng; Yanli He 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 429 KB

Imatinib dose escalation in two patients

Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response

✍ Edgar Faber; David Friedecký; Kateřina Mičová; Martina Divoká; Beata Katrincsáko 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 236 KB